245660-15-5

Basic information

• Product Name: (4-{[tert-butyl(dimethyl)silyl]oxy}butyl)amine
• Synonyms: (4-{[tert-butyl(dimethyl)silyl]oxy}butyl)amine
• CAS NO: 245660-15-5
• Molecular Weight: 203.4
• Mol File: 245660-15-5.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 225.4±23.0 °C(Predicted)
• Density: 0.849±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (4-{[tert-butyl(dimethyl)silyl]oxy}butyl)amine(CAS DataBase Reference)
• NIST Chemistry Reference: (4-{[tert-butyl(dimethyl)silyl]oxy}butyl)amine(245660-15-5)
• EPA Substance Registry System: (4-{[tert-butyl(dimethyl)silyl]oxy}butyl)amine(245660-15-5)

Safety Data

• Hazardous Substances Data: 245660-15-5(Hazardous Substances Data)

Usage

Description

(4-[tert-butyl(dimethyl)silyl]oxybutyl)amine is a complex organic compound characterized by its unique structure that features a tert-butyl(dimethyl)silyl group attached to an oxybutyl chain, which is further connected to an amine group. (4-[tert-butyl(dimethyl)silyl]oxybutyl)amine is known for its versatile reactivity and stability, making it a valuable building block in the synthesis of various organic molecules.

Uses

Used in Chemical Synthesis:
(4-[tert-butyl(dimethyl)silyl]oxybutyl)amine is used as a reactant for the synthesis of various racemic and biotinylation of azamacrocycles. Its unique structure and reactivity make it a valuable component in the creation of complex organic molecules, particularly those with potential applications in the fields of pharmaceuticals, materials science, and chemical research.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (4-[tert-butyl(dimethyl)silyl]oxybutyl)amine is used as a key intermediate in the development of new drugs and therapeutic agents. Its ability to form stable bonds with other molecules allows for the creation of novel drug candidates with improved pharmacological properties, such as enhanced bioavailability, selectivity, and reduced side effects.
Used in Materials Science:
(4-[tert-butyl(dimethyl)silyl]oxybutyl)amine is also utilized in the field of materials science for the development of advanced materials with specific properties. Its incorporation into polymers and other materials can lead to improved mechanical strength, thermal stability, and chemical resistance, making it a valuable component in the design of high-performance materials for various applications.

Upstream product

• 13325-10-5 4-Aminobutanol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1140737-38-7 tert-butyldimethyl-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)butoxy]silane 
• 87184-99-4 4-tert-butyldimethylsilyloxybutan-1-ol 
• 98602-83-6 4-((tert-butyldimethylsilyl)oxy)butyl methanesulfonate 

Downstream Products

• 915065-44-0 N-[2-(benzyloxy)ethyl]-4-{[tert-butyl(dimethyl)silyl]oxy}butan-1-amine 
• 1277190-32-5 N-Boc-N-[4-(t-butyldimethylsilanyloxy)butyl]ethacrynic amide 
• 1277190-31-4 N-[4-(t-butyldimethylsilanyloxy)butyl]ethacrynic amide 
• 1297604-41-1 (E)-3-(4-((4-(benzyloxy)benzyl)oxy)-3-(2-((4-((tert-butyldimethylsilyl)oxy)butyl)amino)-2-oxoethyl)phenyl)-N-(4-((tert-butyldimethylsilyl)oxy)butyl)acrylamide 

Relevant articles and documents

Novel route to the synthesis of hydroxylated piperidine and pyrrolidine derivatives via the intramolecular reaction of γ-aminoallylstannane with aldehyde

The Lewis acid mediated intramolecular reaction of gamma-aminoallyl-stannane 6 gave trans-beta-hydroxypiperidine derivative 7a as a major product. On the other hand, the thermal cyclization of 6 and 8 afforded cis-beta-hydroxypiperidine 7b and pyrrolidine derivative 9b, respectively, with very high stereoselectivity.

NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound of formula (I) comprises at least one covalently bound -ONO2 or -ONO moiety and at most four covalently bound -ONO2 or -ONO moieties, and wherein AR, R1, X, R3 and R4 are as defined in claim 1; and pharmaceutical compositions thereof, and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.

Improved potency and reduced toxicity of the antifungal peptoid AEC5 through submonomer modification

As proteolytically stable peptidomimetics, peptoids could serve as antifungal agents to supplement a therapeutic field wrought with toxicity issues. We report the improvement of an antifungal peptoid, AEC5, through an iterative structure-activity relationship study. A sarcosine scan was used to first identify the most pharmacophorically important peptoid building blocks of AEC5, followed by sequential optimization of each building block. The optimized antifungal peptoid from this study, β-5, has improved potency towards Cryptococcus neoformans and decreased toxicity towards mammalian cells. For example, the selectivity ratio for C. neoformans over mammalian fibroblasts was improved from 8 for AEC5 to 37 for β-5.